2011 Annual Meeting | Neuroimaging and Other Biomarkers for MCI and Alzheimer's Disease

Date Sunday 04/22/12

Time 02:00 PM - 06:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type PM Half-Day Course

Director(s) Sandra E. Black, MD, FAAN

Topic(s) Imaging

Learning Objectives Through illustrative case examples and interactive panel discussion after expert summaries, participants will be able to better evaluate and contextualize accumulating evidence for candidate biomarkers for early detection, prognostication and monitoring progression in AD. Attendees will appreciate the potential role of biomarkers for patient selection and as surrogate outcomes to reduce sample size early in drug development and for evaluating efficacy and safety of emerging treatments. Participants will also gain perspective on which biomarkers are truly ready for clinical application.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Tracks Subspecialty in Focus

Recommended Audience Trainee, General Neurologist, Non-neurologist

Teaching Styles Case-based, Didactic

Event Timeline
02:00 PM - 02:45 PM		Prime Time Versus Pipeline: Cases Illustrating Use of Biomarkers at Different Stages of Alzheimer’s Disease Sandra E. Black, MD, FAAN
02:45 PM - 03:30 PM		Quantitative MRI Biomarkers for Early Detection, Differential Diagnosis, Prognosis and Monitoring in Alzheimer’s Disease Bradford Dickerson, MD, FAAN
03:30 PM - 03:50 PM		Break
03:50 PM - 04:35 PM		The Role of Fluid Biomarkers in Early Detection, Diagnosis, and Monitoring of Alzheimer’s Disease John Kauwe, PhD
04:35 PM - 05:20 PM		The Expanding Role of PET for Early Diagnosis of Alzheimer’s Disease and in Drug Development Norman L. Foster, MD, FAAN
05:20 PM - 06:00 PM		Discussion

Faculty Disclosures
Sandra E. Black, MD, FAAN	Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Hoffmann-La Roche. Dr. Black has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffmann-La Roche. Dr. Black has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai Limited . Dr. Black has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Black has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Black has received research support from Hoffmann-La Roche. The institution of Dr. Black has received research support from Biogen. The institution of Dr. Black has received research support from GE Healthcare. The institution of Dr. Black has received research support from Eli Lilly. The institution of Dr. Black has received research support from Genentech. The institution of Dr. Black has received research support from NovoNordisk. The institution of Dr. Black has received research support from UCB Biopharma. The institution of Dr. Black has received research support from Alkahest Inc. The institution of Dr. Black has received research support from University of Southern California - AHEAD 3-45 Study.
Norman L. Foster, MD, FAAN	No disclosure on file
Bradford Dickerson, MD, FAAN	Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arkuda. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lantheus. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Dickerson has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arkuda. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Dickerson has received publishing royalties from a publication relating to health care. Dr. Dickerson has received publishing royalties from a publication relating to health care.
John Kauwe, PhD	No disclosure on file

��ɫ��

��ɫ��